(MRUS) Announces Closing of Partial Exercise of Underwriters’ Over-Allotment Option

UTRECHT, the Netherlands, May 31, 2016 — Merus N.V. (“Merus”) (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics, today announced the closing of a partial exercise of the over-allotment option by the underwriters of its previously announced initial public offering in the amount of an additional 639,926 common shares at the initial public offering price of $10.00 per share. The sale of the additional shares closed on May 26, 2016, bringing the total number of common shares sold by Merus in its initial public offering to 6,139,926. Including the proceeds from the sale of the additional shares, the total net proceeds, after deducting the underwriting discounts and commissions and estimated offering expenses, to Merus from its initial public offering are approximately $53.3 million.

Citigroup Global Markets Inc. and Jefferies LLC acted as joint book-running managers for the offering, Guggenheim Securities, LLC acted as lead manager for the offering and Wedbush PacGrow acted as co-manager for the offering.

A registration statement relating to these securities was declared effective by the U.S. Securities and Exchange Commission on May 18, 2016. The offering was made only by means of a prospectus.  Copies of the final prospectus relating to the offering may be obtained by contacting Citigroup by mail, c/o Broadridge Financial Solutions, at 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (800) 831-9146, or by email at prospectus@citi.com; or Jefferies LLC, by mail at 520 Madison Avenue, 2nd Floor, New York, New York 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340 or by email at prospectus_department@jefferies.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.

Contact Information:

Investor Relations
Argot Partners
Eliza Schleifstein – eliza@argotpartners.com
1-917-763-8106